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“Soldier’s Heart,” is an American Civil War term linking post-traumatic stress
disorder (PTSD) with increased propensity for cardiovascular disease (CVD). We have
hypothesized that there might be a quantifiable genetic basis for this linkage. To test
this hypothesis we identified a comprehensive set of candidate risk genes for PTSD,
and tested whether any were also independent risk genes for CVD. A functional analysis
algorithm was used to identify associated signaling networks. We identified 106 PTSD
studies that report one or more polymorphic variants in 87 candidate genes in 83,463
subjects and controls. The top upstream drivers for these PTSD risk genes are predicted
to be the glucocorticoid receptor (NR3C1) and Tumor Necrosis Factor alpha (TNFA). We
find that 37 of the PTSD candidate risk genes are also candidate independent risk genes
for CVD. The association between PTSD and CVD is significant by Fisher’s Exact Test
(P= 3× 10−54). We also find 15 PTSD risk genes that are independently associated with
Type 2 Diabetes Mellitus (T2DM; also significant by Fisher’s Exact Test (P= 1.8× 10−16).
Our findings offer quantitative evidence for a genetic link between post-traumatic stress
and cardiovascular disease, Computationally, the common mechanism for this linkage
between PTSD and CVD is innate immunity and NFκB-mediated inflammation.
Keywords: post traumatic stress disorder, cardiovascular disease, Type 2 diabetes mellitus, candidate gene
INTRODUCTION
Soon after the end of the American CivilWar, Dr. JacobMendezDa Costa, a Philadelphia physician,
reported evidence linking what we now term post-traumatic stress disorder (PTSD) with increased
risk for cardiovascular disease (CVD; Wooley, 1982). Based on analysis of ca. 300 soldiers in a
dedicated hospital in wartime Philadelphia, Da Costa’s report may have been the first ever example
of a modern “big data” clinical study. Da Costa termed the relationship “soldiers heart ” or “irritable
heart,” More recently, this relationship has been described in different groups of combat veterans
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and civilians with PTSD (Cwikel et al., 1997; Paulus et al.,
2013; Sidney, 2013; Turner et al., 2013; Wentworth et al., 2013;
Beristianos et al., 2014; Roy et al., 2015). Until very recently,
there was no biological evidence to link PTSD to CVD. However,
the possibility of a genetic mechanism for the link was recently
raised by twin studies from the Viet Nam Era Twin (VET)
Registry (Vaccarino et al., 2013). This study showed that if both
twins had PTSD, the risk of CVD was doubled in both twins.
Strikingly, the increased risk was unrelated to smoking, blood
lipids, obesity or lack of exercise. By contrast, no significantly
increased familial risk for Type II diabetes could be found
in the same cohort (Vaccarino et al., 2014). Together, these
epidemiological and experimental data suggest that a hitherto
unknown genetic mechanism might be responsible for the link
between PTSD and CVD.
However, to determine what common genetic mechanisms
might be responsible, a systems biology approach must
be deployed. Alternative approaches include Genome Wide
Association Studies (GWAS), Whole Exome Sequencing (WES),
Whole Genome Sequencing (WGS), and Candidate Gene
Analysis (CGA). However, recent GWAS for PTSD have
provided limited evidence of association for specific loci (Andero
et al., 2013; Logue et al., 2013; Xie et al., 2013; Stein et al.,
2016). GWAS studies are based on finding a significant
association between disease and up to 500,000 single nucleotide
polymorphisms (SNPs) which are randomly distributed in the
3.6 Billion base human genome. Thus, a 500,000 SNP survey
hopes to find a genome-wide disease association by targeting just
0.16% of the genome. If successful in discovering a significant
association for a SNP, or set of SNPs, with disease, the next
step is to look for a gene near the SNP and impute that nearby
gene for association with the disease. Significance is based on
the Bonferroni correction formultiple comparisons. A significant
p-value based on this correction is computed by dividing the
standard p-value for significance (e.g., 0.05) by the number of
comparisons (viz, corrected p = 0.05/500,000 = 1 EXP-7; EXP-7
also means 1 × 10−7). Thus, a p-value equal to or less than 10−7
would be nominally significant.
Thus, in the largest study to date in a military ArmySTARRS
population, ANKRD55, on chromosome 5, was imputed from a
significant association (p = 2.34 EXP-8) at rs159572. This SNP
(single nucleotide polymorphism) was located within an intron
of the ANKRD55 gene in African Americans only (Stein et al.,
2016). By contrast, in the same study, a significant association for
European-Americans was imputed for ZNF626 on chromosome
19 (p = 4.59 EXP-8). Furthermore, no significant associations
were observed for Latinos or in any of the transethnic meta-
analyses. In a different study on a smaller group from the
military, with non-hispanic and African American subcohorts,
the retinoid-related orphan receptor alpha (RORA) was imputed
from a significant association (p = 5 EXP-8) with the SNP
at rs8042149 (Logue et al., 2013). Importantly, this SNP was
also located within the RORA gene itself. However, in spite
of a similar African American cohort, the SNP at rs159572,
imputing ANKRD55, was not found. Finally, Xie et al. (2013),
studying a racially mixed civilian cohort, identified a significant
SNP (p = 3.97EXP-8) at rs406001 for the European American
population only. However, no candidate gene could be imputed
from this SNP. Thus, these three most recent and best powered
studies do not replicate each other, even though the individual
associations from these studies are significant, and the identifying
SNPs for two of the differently imputed genes are located
within their respective gene sequences. Furthermore, the systems
biology approach cannot be deployed without a pattern of PTSD-
associated SNPs, to compare with parallel data from CVD. We
therefore conclude that it is not yet possible to deduce common
candidate risk genes for PTSD from GWAS data alone.
However, WES and WGS are emerging technologies which
have not yet been deployed for PTSD. Therefore, to test
the hypothesis of a genetic basis for the connection between
PTSD and CVD, we are left presently only with the Candidate
Gene approach. The Candidate Gene approach depends on
collecting and analyzing genes tested for disease association
based on a hypothesis-driven approach by investigators, based
on knowledge or intuition regarding the disease of interest.
Although this strategy is potentially conflicted by investigator
bias, the bias can be diluted out by a large number of studies, and
has been used as a bootstrap to enhance focused genomic analysis
of complex traits. Recent examples include asthma (Michel et al.,
2010) and obesity (Kim et al., 2012). Therefore, as a first step
toward the candidate gene approach, we identified 106 PTSD
studies that report one or more polymorphic variants in 87
candidate PTSD risk genes in 83,463 subjects and controls.
We then asked (1) whether any of the PTSD risk genes
overlapped with an equivalent list of independent risk genes
for either CVD or T2DM: there were 36 and 15 respectively;
(2) whether the associations were significant: they were; and
(3) whether an informatics-based analysis might identify shared
signaling pathways; they did, emphasizing the NFκB complex
and downstream proinflammatory signaling. We conclude that
these data provide mechanistic evidence of a genetic link between
susceptibility to both PTSD, cardiovascular disease, and to a
lesser extent Type 2 Diabetes Mellitus. However, we suggest that
validation of this conclusion will necessarily depend on future
WGS of well-phenotyped PTSD populations.
RESULTS
Identification of Candidate Genes
Associated with Increased Risk for PTSD
The results of our survey of candidate risk genes reported for
PTSD are summarized alphabetically in Supplementary Table 1.
They include the results of 106 studies reporting one or more
polymorphic variants in 87 genes in 83,463 subjects and controls.
We employed a manual curation approach to this analysis, in
order to ensure that the claim in each study was fully validated
by the data presented. No meta-data analyses were performed.
Immediate inspection of Supplementary Table 1 indicates that
at least 13 of these genes have been reported by more than
one group of investigators. These include adenylate cyclase
8 (brain) (ADCY8); adenylate cyclase activating polypeptide
1 (pituitary) receptor type 1 (ADCYAP1R1); brain derived
neurotropic factor (BNDF); catechol-O-methyltransferase
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COMT); chemokine (C-X-C) ligand 8 (IL-8); dopamine receptor
2(DRD2); FK506 binding protein 5 (FKBP5); interleukin 1beta
(IL1B); glucocorticoid receptor (NR3C1); regulator of G protein
signaling 2 (RGS2); neuronal/epithelial high affinity glutamate
transporter (SLC1A1); dopamine transporter (SLC6A3);
serotonin transporter (SLC6A4); and tryptophan hydroxylase
2 (TPH2). These genes thus survive at least one conventional
candidate gene test of reproducibility, while the others on the list
remain to be tested in more than one venue.
However, it is yet to be determined whether the variants
for these genes, or others on the list, effect increased risk
for PTSD for only some populations. For example, some
of these reported PTSD risk genes have been specifically
associated in their respective literatures with sub-populations
of varying ethnicity and genders. Examples include Tryptophan
Hydroxylase 1 (TPRH; found in Spitak earthquake survivors),
5-Hydroxytryptamine Receptor 2A (5-HT2A: only reported
for an African American population; possibly only in females);
Adenylate Cyclase Activating Polypeptide 1 (Pituitary) (Receptor
Type 1 (PACAPR: females but not males); Corticotropin
Releasing Hormone Receptor 1 (CRHR1: post hurricane
survivors); Regulator of G-Protein signaling 2 (RGS2, GOS8:
post hurricane survivors); Steroid-5 Alpha Reductase, Alpha
Polypeptide 2 (SRD5A2: males but not females); Stathmin
1 (SMN: females only, in the Wenchen earthquake); WW
and C2 Domain Containing 1 (KIBRA, PPP1R169: in an
African population); Tolloid-like-1 (TLL1: identified in
European/Hispanic American but not African American combat
veterans); and Phosphoribosyltransferase Domain Containing 1
(PRTFDC1: applicable to multiple ethnicities, including Native
American). Thus, there may be ethnic and gender-dependent
heterogeneity in the complete list. However, this potential
problem cannot be known with certainty, given the variable
numbers of subjects and controls in each cohort, the consequent
questions of statistical power, and the limitations of previously
available genetic tools.
Signaling Pathways and Networks
Associated with PTSD Susceptibility Genes
It was therefore possible that genetic risk for PTSD susceptibility
might have such considerable allelic variation that considering
the entire group for analysis might be overwhelmed by this
heterogeneity. However, network science, especially for the
primate brain, can provide strong inference suggestions as
to function (Dalgard et al., 2015; Mears and Pollard, 2016).
Analogous to airline destination maps which describe major
airport hubs and feeder connections to minor airports, pathway
analysis software can use interaction data mined out from
the literature to discern such relationships among genes and
proteins. The relationships include disease-relevant pathways,
predicted causal (upstream) drivers, and calculations of statistical
significance based on the number of genes known to be
in a specific pathway relative to the number of genes in
the experimental sample. Therefore, to identify PTSD-specific
signaling pathways and calculate significance, we used the
Ingenuity Pathway Analysis (IPA) software. IPA is one of the
more widely used proprietary recipes, or algorithms, for this
purpose.
The IPA analysis software used to analyze these 83 candidate
PTSD risk genes as a group, allowed us to identify a limited
number of highly significant, biologically relevant, Canonical
Pathways and Associated Networks. As shown in Figure 1A, the
4 top highly significant Canonical Pathways include G-Protein
Coupled Receptor Signaling (P = 2.32E-11), Serotonin Receptor
Signaling (P = 3.92E-11); cAMP-mediated signaling (P =
1.01E-09); and Dopamine Receptor Signaling (P = 2.43E-08). As
shown in Figure 1B, the algorithm also identified “Neurological
Disease...” (Network #1) and “Nervous System Development and
Function...” (Network #2) as the principal predicted functional
consequences when all 83 genes were considered together. These
data are thus generally consistent with what might be expected
from an analysis of a brain-centric psychiatric disease like PTSD.
For the case of Network #1 (Figure 1B), 22 of 26 nodes in
this graph are genes from the complete set of 83. Figure 1C
shows the principal hubs which integrate these genes, including
CREB (cAMP response element binding protein: 13 of 26
nodes) and Protein Kinase C (12 of 26 nodes). The hubs
shown are in descending order of connectedness, and thus
possibly in descending order of importance for control of PTSD
susceptibility. For the case of Network #2 (Figure 1D), 11 of
27 nodes in this graph are genes from the complete set of 83.
Figure 1E shows the principal hubs which integrate these genes,
including ERK1/2 (22 of 27 nodes) and AKT (Protein Kinase
B: 21 of 27 nodes). Importantly, nodes for genes or functions
that not in the original set of 83 genes are not necessarily
“false positives”; rather they have traditionally been viewed as
representing candidate genes or functions for further study.
Network #2, for example, includes proinsulin, PI3K, AMPK and
MHC Class II, genes or functions which may become of interest
in a later part of this paper. However, comprehensively, the two
networks together represent 33 genes (viz., ca. 40% of the total).
By using the causal analytics tool “Upstream Regulator
Analysis” within the IPA program, we were next able to test
whether there might be an upstream integrating mechanism
which could act as a “regulator” for PTSD-related risk genes.
The advantage of causal network analysis is that it integrates
previously observed cause-effect relationships reported in the
literature, and is more powerful than gene set enrichment alone
since it leverages knowledge about the direction of effects rather
than mere associations (Krämer et al., 2014). In addition, if the
causal effect of one regulator depends on another in the network,
then both regulators should be identified. Figure 2A shows the
top five statistically significant upstream regulators for the entire
set of 83 PTSD risk genes. These include (i) the glucocorticoid
receptor (NR3C1, P = 1.5 E-12); (ii) Tumor Necrosis Factor
alpha (TNFα, P= 3.49E-12), (iii) NLRP12 (P= 3.40E-10) PTGS2
(P = 3.40 E-10); and (iv) Interleukin 1 beta (IL-1β, P = 3.71E-
10). What is generally true about these five genes is that they
all are related in some way to the process of inflammation.
Figure 2B graphs the predicted downstream relationships among
the top two regulators: TNFα and the glucocorticoid receptor.
What is apparent from this graph is that the two regulators
have different downstream consequences, reminiscent to some
extent of Networks #1 and #2 (see Figures 1B,D). However, the
overlap focuses on the “NFκB Complex” (Chen and Greene,
2004), and its activating cytosolic component RELA (NFκB, p65),
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FIGURE 1 | Functional relationships among 83 candidate PTSD genes. (A) Top canonical pathways. Two top signaling pathways are G-Protein Coupled
Receptor and Serotonin Receptor signaling. (B) Associated network Function #1. CREB and PKC are top hubs in this network. (C) Inset: Network #1, top 5 hubs. (D)
Associated network Function #2. ERK1/2, AKT, ERK, and p38MAPK are top hubs in this network. (E) Inset: Network #2, top 5 hubs.
and its inhibitory cytosolic components NFKB1A (IκBα), and
NFKB1(NFκB, p105). These internode interactions are marked
in red. It would therefore appear that upstream regulation
of the PTSD risk genes might be dominantly regulated by
proinflammatory signaling mechanisms. Figure 2C shows that
the top predicted toxicology list is headed by cardiac hypertrophy
(P = 5.34E-09) and liver damage (P =9.17E-09).
Identification of Candidate PTSD-Risk
Genes for Which Mutations are Also
Associated Independently with Increased
Risk for Cardiovascular Disease
To test the hypothesis that any of the 87 candidate risk genes
might overlap with risk genes for CVD, we utilized a published
set of candidate cardiovascular disease (CVD) risk genes [163
genes (Gibbons et al., 2004)]. We also included an additional 309
imputed genes from more recent GWAS data that had assigned
risk factors of at least 10% (Cambien and Tiret, 2007; Whitfield,
2014). However, independent validation of GWAS- imputed
risk genes has been a challenge (Simon et al., 2016). As shown
in Supplemental Table 1 (see “YES” in the CVD column), 36
candidate CVD risk genes are common to both PTSD and CVD.
Not unexpectedly, none of the GWAS-imputed CVD risk genes
overlapped with the candidate PTSD risk genes. The association
between candidate PTSD risk genes and candidate CVD risk
genes is statistically significant (Fisher’s exact test on a 2X2
table [19790, 127;47,36], assuming 20,000 genes in the genome;
p= 3× 10E-54).
A portion of the IPA analysis of this set of 36 CVD
genes is shown in Figure 3. Figure 3A shows that the top
highly significant Canonical Pathways are dominated by
immune functions. These include Role of Cytokines Mediating
Communication between Immune Cells (P = 5.75E-10);
Communication between Innate and Adaptive Immune Cells
(P = 1.13E-08); Role of Hypercytokinemia/Hyperchemokinemia
in the Pathogenesis of Influenza (essentially “cytokine storm,”
P = 1.45E-08); and Graft-vs.-Host Disease signaling (P = 2.02E-
08). In support of these signaling pathways are the top two
Networks. In the case of Network #1 (Figure 3B: “Neurological
Disease, Psychological Disorders, Skeletal and muscular
disorders”), 11 of 33 nodes in this graph are genes from the
complete set of 36 CVD risk genes. Figure 3C shows that TNFα is
the principal hub which integrates all of the nodes made up of 11
CVD genes and 22 other genes and functions which are inferred
to be connected to this set of genes. Other hubs, including PKC,
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FIGURE 2 | Upstream regulation of risk genes for PTSD. (A) Predicted Top Five Upstream Regulators. The top two are NR3C1 (Glucocorticoid Receptor) and
TNFα. (B) Predicted Targets of top two upstream regulator, NR3C1 (Glucocorticoid Receptor) and TNFα. (C) Predicted Top Tox (icology) Functions. Top tox function is
cardiac hypertrophy.
PKA, IL-1RN and CNR1, interact with progressively fewer of
the nodes and are presumably progressively less important. For
the case of Network #2 (Figure 3D: “Psychological Disorders,
Neurological Disease, Organismal Injury and Abnormalities”),
9 of 31 nodes are genes from the complete set of 36 CVD
risk genes. Figure 3E shows that the top two hubs are IL-1β
and IL-2, followed by hubs with progressively fewer links:
ERK1/2, P38MAPK and AKT/PKB. Network #2 shares no CVD
genes with Network #1, and together they therefore provide an
integrating mechanism for 20 (viz., 56%) of the 36 CVD risk
genes. Note that four of the top 5 hubs for the CVD Network
#2, are also in the top 5 hubs for the PTSD Network #2 (viz.,
compare Figure 3E with Figure 1E). However, only two genes,
IL-2 and BDNF, are nodes in both networks. These relationships
suggest that both the complete set of 83 PTSD risk genes, and
the sub-set of 36 CVD risk genes, may share at least one genomic
signature.
We next used the causal analytics tool “Upstream Regulator
Analysis” to test whether there might be an upstream integrating
mechanism which could act as a “regulator” for the subset of 36
CVD risk genes. Figure 4A lists the predicted top five upstream
CVD regulators, two of which, NLRP12 and TNFα, are the
same upstream regulators as those predicted for the complete
set of 83 PTSD risk genes (see Figure 2A). Of the remaining 3
regulators, NR1H2 (LXRB) and NR1H3 (LXRA) form a family
of heterodimers that control both lipid homeostasis (Schultz
et al., 2000) and inflammation (Joseph et al., 2003). Furthermore,
recent twin and family GWAS studies have identified LXRA
and LXRB genes in signatures for coronary artery disease and
hepatic steatosis, and have been interpreted to have broad effects
on multiple metabolic traits (Rankinen et al., 2015). The fifth
predicted regulator, c-IAP2, is an anti-apoptosis gene which
inhibits inflammation-associated TNF receptor signaling and
controls downstream NFκB activation (Mayer et al., 2011). c-
IAP2 also protects cardiac fibroblasts through suppression of
ERK1/2 MAPK and NFκB signaling (Philip and Shivakumar,
2013). Finally, as shown in Figure 4B, the top two regulators,
NLRP12 and TNF, identify elements in the NFκB complex as the
relevant targets for the Regulators. Therefore, whether working
with either the 87 candidate risk genes for PTSD (see Figure 2B),
or the sub-set of CVD risk genes (see Figure 4B), the same NFκB
complex is strongly identified as a common set of downstream
targets. Consistently, Figure 4C identifies cardiotioxicity as the
top toxicology function for the CVD risk genes. Included in this
function are infarction, arteriopathy, arrhythmia, heart failure,
and congestive heart failure. However, given that this sub-set of
36 PTSD genes were all identified as independent risk factors for
CDV, this prediction may not be unexpected.
Identification of Candidate PTSD-Risk
Genes for Which Mutations are Also
Associated Independently with Increased
Risk for Type 2 Diabetes Mellitus
As a possible “control” for the association between PTSD and
CVD risk genes, we tested for a relationship between candidate
PTSD risk genes, and candidate genes for Type 2 Diabetes
Mellitus (T2DM). The rationale for this choice was that results
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FIGURE 3 | Functional relationship among 36 candidate PTSD genes, which share an independent risk factor status with cardiovascular disease. (A)
Top canonical pathways. The top signaling pathway is Role of Cytokines in Mediating Communication between Immune Cells. (B) Associated Network Function #1.
The top hub is TNFalpha, (C) Inset: Network #1, top 5 hubs. (D) Associated Network Function #2. The top hubs are IL-1β, IL-2, p38MAPK, and ERK1/2. (E) Inset:
Network #2, top 5 hubs.
from the Viet Nam Twins study had shown a familial relationship
between PTSD and CVD (Vaccarino et al., 2013), but failed to
show a familial relationship for PTSD and T2DM (Vaccarino
et al., 2014). For consistency, we utilized a recently published
T2DM risk gene set comprised of 106 candidate genes (Kluth
et al., 2014). We then calculated the overlap of the T2DM risk
gene set and the CVD risk gene set. As shown in Supplementary
Table 1, only 15 genes (18%) of the PTSD risk genes were also risk
genes for T2DM (see). However, this enrichment was statistically
significant (Fisher’s exact test on a 2X2 table [19769, 148; 68,
15], assuming 20,000 genes in the genome, P = 1.8 × 10−16.
Furthermore, of these 15 genes, 14 were also in the CVD category.
To further test for the enrichments of PTSD risk genes in the
CVD gene set vs. the PTSD enrichment in the T2DM gene set,
we compared odds ratios. The odds ratio for PTSD and CVD
enrichment was 118.9 (95% CI, [72.4-195.4]). By contrast, the
odds ratio for the PTSD and T2DMenrichment was 29.4 (95%CI,
[15.26-53.4]). Because the PTSD and CVD odds ratio was greater
than the PTSD and T2DM odds ratio, we conclude that PTSD
and CVD enrichment is significantly greater than the PTSD and
T2DM enrichment. However, it remains important to take into
consideration that these odds ratios are not independent.
Figure 5A shows that the Canonical Pathways for T2DM risk
genes concentrate on immune functions. This was also the case
for the set of 34 CVD risk genes; however, for the T2DM risk
genes, the specific Canonical Pathways are quite different. Here,
these include Acute Phase Response Signaling (P = 1.01E-07);
Regulation of cytokine production in macrophages and T helper
cells by IL-17A and IL-17F (P = 2.57E-07); glucocorticoid
receptor signaling (P= 1.12E-06); and IL-6 signaling (P= 1.26E-
06). Of potential concern is the fact that the P-values for these
Canonical pathways are substantially elevated compared to the
PTSD risk genes (see Figure 1A) and CVD subset of risk genes
(see Figure 3A). However, this finding is very likely dependent on
the relatively reduced number of total T2DM risk genes available
for analysis, and serve as a signpost of the relative paucity of genes
in this category, no matter how statistically significant.
The two top Associated Networks for this system are
shown in Figures 5B,C, respectively. Network #1 (Figure 5B)
is built from only 4 of the 15 T2DM genes, and is marked
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FIGURE 4 | Upstream regulation of risk genes for CVD. (A) Predicted Top upstream Regulators. The top two are NLRP12 and TNFa. (B) Predicted Targets of top
two upstream regulator, NLRP12 and TNFa. (C) Predicted Top Tox (icology) Functions. All five describe cardiac disease.
uniquely by a heavily populated hub for IL-6, and progressively
less for 4 mitogen-related genes (see Figure 5C). Network #2
(Figure 5D) is built from 6 of the 15 T2DM genes, and contains
heavily populated hubs for TNFa and IL-1β. (see Figure 5E).
Progressively fewer linked hubs for Network #2 include the IL-
12 complex, apolipoprotein E, and the PI3K complex. Thus, both
Associated networks together account for 10 (66.67%) of the
15 T2DM genes. It is also apparent, regardless of significantly
different gene numbers, that TNFα and ERK1/2 are major hubs
for both CVD risk genes and T2DM risk genes, and that ERK1/2
is also a major hub for one of the network describing the parental
set of PTSD risk genes.
Figure 6A shows the top five predicted upstream regulators
for T2DM risk genes. This list is dominated by the now
familiar transcription factors, LXRB and LXRA, and with
lesser significance by three other genes: APP (amyloid (A4)
Precursor Protein); (CNR1) (cannabinoid Receptor 1) and
THBD (thrombomodulin). Consistent with the results from
the CVD risk genes (see Figure 5B), the targets for the top
upstream regulator, NH1H2/LXRB include the NFκB complex
and associated NFκB drivers and inhibitors (see Figure 6B). The
top toxicology lists (Figure 6C) focuses on three cardiovascular
dysfunctions, and with lower significance both LXR/RXR
activation. These address lipid homeostasis and inflammation,
and oxidative stress. In retrospect, the fact that 14 of 15
T2DM risk genes are the same as both PTSD and CVD risk
genes suggests that the parallel between CVD and T2DM in
terms of predicted Canonical Pathways, predicted Associated
Networks, and predicted Upstream Regulators should not be
unexpected. However, there are quantitative and qualitative
differences suggesting that the risk for CVD in PTSD patients
may be unique from T2DM risk.
DISCUSSION
Beginning with the first “soldier’s heart” study by Da Costa
following the American Civil War, and continuing to the
present wars with ever increasing epidemiological sophistication,
susceptibility to PTSD following of exposure to intense emotional
and physical stress has been found to be accompanied by an
increased risk for CVD (Roy et al., 2015). The network analysis
of candidate gene studies we report here has permitted us to test
the hypothesis that the relationship between PTSD and CVD
is genetic, and to conclude that the hypothesis has strong and
significant support from the available data. (Gill et al., 2009; Gola
et al., 2013; Zhou et al., 2014; Breen et al., 2015). Furthermore,
the mechanistic driver linking common susceptibility to PTSD
and CVD identifies the NFκB complex (viz, [NFκB, p105],
[NFκB, p65], and [IκBα]). These are the targets of the
principal upstream regulators for PTSD and PTSD/CVD risk.
These data are thus quite coherent with a lengthy literature,
including a recent strain-specific mouse model system (Cho
et al., 2014), implicating inflammation as a mechanism for
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FIGURE 5 | Functional relationship among 15 candidate T2DM genes, which share an independent risk factor status with PTSD. (A) Top canonical
pathways. The top signaling pathway is Acute Phase Response Signaling. (B) Associated Network Function #1. The top hubs are IL-6, ERK1/2, ERK, and AKT. (C)
Inset: Network #1, top 5 hubs. (D) Associated network Function #2. The top hubs are TNFα, IL-1β and IL-12. (E) Inset: Network #2, top 5 hubs.
the biological consequences of both post-traumatic stress and
cardiovascular disease. Collectively, these results therefore tend
to support a genetic hypothesis for susceptibility to PTSD and
concomitant cardiovascular disease, involving a common NFκB-
associated proinflammatory mechanism. In addition, the data
also support the concept that there may also be a modest but
still significant genetic link between the risk for PTSD and
the risk for T2DM. Finally, as a manual complement to the
computational focus of the IPA program on NFκB signaling as
an integrating upstream mechanism for the PTSD/CVD genetic
link, Figure 7 summarizes concrete examples from the literature,
which experimentally connect the principal candidate PTSD and
CVD risk gene hubs to activation or inhibition of NFκB signaling,
and in some cases to each other (Shirakawa and Mizel, 1989;
Shirakawa et al., 1989; Libermann and Baltimore, 1990; Maliner-
Stratton et al., 2001; Chen and Roper, 2003; Davis et al., 2003;
Nair and Sealfon, 2003; Patel et al., 2003; Sánchez et al., 2003;
Zhou et al., 2003; Takeuchi and Fukunaga, 2004; Gustin et al.,
2004a,b; Howlett, 2005; Gao et al., 2006; Li et al., 2007; Saperstein
et al., 2009; Wang et al., 2009; Wen et al., 2010; King et al., 2011;
Wang V. Y. et al., 2012; Wang X. et al., 2012; Chiang et al.,
2013; Kim et al., 2013; Liao et al., 2013; Wesche et al., 2013;
Liu et al., 2014; Gonzalez et al., 2015). So, the analysis does not
just depend on a computer search of the literature, but can be
validated manually.
However, there are important caveats for data marshaled
here in support of the genetic hypothesis for PTSD/CVD
susceptibility. Firstly, the PTSD risk gene data are based
mostly on candidate genes identified from the literature,
independent of statistical association. Candidate genes are chosen
by investigators based on hypothesis and logical connections
to previous studies (Tabor et al., 2002). However, as alluded
to above, there was no choice: GWAS studies for PTSD risk
genes have been inconsistent with respect to specific loci. For
consistency, we used the same approach for both CVD genes
and T2DM risk genes. By contrast, GWAS studies have been
productive for CVD and T2DM. However, when we extended the
CVD and T2DM lists to include imputed genes from respective
GWAS studies, no overlaps with the candidate PTSD gene set
were found.
A second caveat is the problem of knowing exactly how
many genes are actually in the categories of risk for specific
chronic diseases. In the case of candidate risk genes for
PTSD, we used both manual curation and recourse to multiple
databases to deduce the specific number. In the case of
independent candidate risk genes for CVD, we found at least
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FIGURE 6 | Upstream regulation of risk genes for T2DM. (A) Predicted Top Upstream Regulators. The top two are LXRA and LXRB. (B) Predicted targets of the
top upstream regulator, LXRB. (C) Predicted Top Tox (icology) Lists. The emphasisis on cardiac disease.
163 genes, and used this number for statistical calculations.
We conditionally included 309 CVD risk genes deduced from
GWAS studies, associated with at least 10% of the CVD risk
(Cambien and Tiret, 2007; Whitfield, 2014). In addition, the
HUGE and other databases reach out to at least 1.5% CVD
risk, identifying approximately 1080 candidate risk genes. For
consistency, we wanted to use equivalent candidate risk genes
for the T2DM comparison. For this purpose we found 106
candidate risk genes for Type 2 Diabetes, which had not
been specified as to proportional to risk (Whitfield, 2014).
Finally, as pointed out recently, the number of significant
loci for coronary artery disease and T2DM is proportional
to the number of subjects in a GWAS study (Whitfield,
2014). Thus, the GWAS approach alone is intrinsically
underpowered with respect to complete identification of disease
risk genes.
A third caveat is that both male and female studies have
been analyzed together, as have all ethnicities. It may be that
females are more susceptible to PTSD than males, as has been
frequently reported. However, the largest number of samples
from single cohorts have been males from military cohorts. We
do not have many females from the same type of military cohort.
Rathermost of the female cohorts come from such geographically
diverse experiences with earthquakes and hurricanes. However,
in addition to gender there were also ethnic diversity to
consider: Europeans per se, European Americans, Africans,
African Americans, Pacific Islanders, Asians, Southeast Asians,
Hispanics and Native Americans. Faced with such diversity we
grouped all patients together as the most stringent test for some
common mechanism.
A final caveat is the realization that to comprehensively
test the genetic hypothesis for PTSD/CVD susceptibility, it
will be necessary focus solely on WGS. In case there was any
doubt about the value of WGS relative to the GWAS-based
gene imputation method, Wood et al. (2015) found that of 90
low-frequency signals detectable by WGS of 450 individuals,
from the InCHIANTI aging study, 57 (i.e., 63%) could not
be detected using GWAS imputation alone. Importantly, these
authors also determined that single-variant low frequency large
effect signals represented only 7% of detectable signals. Whole
Genome Sequences from large numbers of well-curated patients
and controls is the core strategy in the Precision Medicine
paradigm. This paradigm therefore needs to be applied to the
problem of identifying the genetic mechanisms, if they exist,
which are responsible for common susceptibilities to PTSD, CVD
and T2DM (Insel, 2014; Wood et al., 2015).
Conclusions
Based on a manually curated, computer-assisted, comprehensive
analysis of previously published candidate gene studies, we
find evidence for a genetic basis for the highly significant
parallel susceptiblity to PTSD and CVD by soldiers and civilians
exposed to extreme stress. There may also be evidence from this
analysis for a genetic linkage between PTSD and T2DM. Our
findings further suggest that the fundamental genetic mechanism
may involve upstream NFκB-mediated inflammation. However,
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FIGURE 7 | NFkB Complex is the focus of principal hubs for PTSD and
CVD risk genes. The NFkB Complex is identified specifically by the IPA
algorithm to include the cytosolic inhibitors [NFκB, p105] and [IκBα], and the
driver [NFκB, p65]. Numbers attached to each arrow are example references
from the experimental literature, which document activator functions (arrows)
or inhibitor functions (T-endings) between genes. Many of the NFkB-driven
genes also interact with each other. When making predictions regarding
mechanism, the IPA algorithm takes these interactions into account by
reference to its “master” network of information from the Ingenuity Knowledge
Base. The numbers correspond to the following references. 28. Wang et al.,
2009; Wen et al., 2010; 29. Saperstein et al., 2009; 30. Shirakawa and Mizel,
1989; 31. Chiang et al., 2013; 33. Kim et al., 2013; 34. King et al., 2011;
35. Shirakawa et al., 1989; 36. Zhou et al., 2003; 37. Gonzalez et al., 2015;
38. Takeuchi and Fukunaga, 2004; 39. Nair and Sealfon, 2003; 40. Li et al.,
2007; 41. Sánchez et al., 2003; 42. Howlett, 2005; 43. Gustin et al., 2004a;
44. Gustin et al., 2004b; 45. Chen and Roper, 2003; 46. Davis et al., 2003;
47. Wang X. et al., 2012; 48. Wesche et al., 2013; 49. Wang V. Y. et al., 2012;
50. Gao et al., 2006; 51. Patel et al., 2003; 52. Maliner-Stratton et al., 2001;
53. Libermann and Baltimore, 1990; 54. Liao et al., 2013; 55. Liu et al., 2014.
a precision medicine approach, with larger numbers of
well-curated PTSD patients, are needed to comprehensively
test both the genetic hypothesis and the candidate genetic
mechanism.
EXPERIMENTAL PROCEDURES
Selection of Genes
The data analyzed here for PTSD and CVD were locked in
as of May 25, 2015. The data for Type 2 Diabetes mellitus
were locked in as of May 26, 2015. For selection of genes,
the following databases were searched: PubMed, GWAS catalog
from NIH, HuGE navigator and PILOT (Published International
Literature On Traumatic Stress) database from the Department
of Veterans Affairs. When using PubMed and PILOT database
used different keywords (see below): (a) “PTSD”; (b) “Post
traumatic stress disorder”; (c) “PTSD and genomics”; (d) “PTSD
and SNPs”; (e) “PTSD & Variants”; (f) “Post traumatic stress
disorder” and “genomics”; (g)“Post traumatic stress disorder”
and “SNPs”; (h)“Post traumatic stress disorder” and “variants”;
(i) “PTSD” and “GWAS”’ (j) “Post traumatic stress disorder” and
“GWAS”. When using the GWAS catalog from NIH, we selected
“PTSD” [from the list] for the “disease” section, and used default
setting to retrieve the data. In the HuGE navigator, we used the
“Pheopedia” and used the disease term “Stress disorders, post-
traumatic”. In both cases, we looked at all the publications for
significant SNPs on the results/summary or discussion section.
We manually read every referenced article to test validity of
the claim, and to identify the specific mutation reported. The
data for PTSD and the CVD and T2DM subcategories are
comprehensively summarized in Supplementary Table 1. By way
of a caveat for these “YES” genes, the same concerns regarding
power and significance noted for PTSD risk genes also apply to
the data for independent CVD risk genes. Nonetheless, candidate
gene data have their own coherence and structure, and can
explicitly be compared with other data collected in the same
manner.
IPA Algorithm
The functional analysis algorithm from Ingenuity Pathway
Analysis (IPA; Ingenuity Systems, http://www.ingenuity.com)
was used to identify the top canonical pathways, top predicted
diseases and disorders associated with these canonical pathways,
top physiological systems, and top associated networks. The
algorithm transforms a list of genes into a set of relevant
networks based on extensive records maintained in the Ingenuity
Knowledge Base (IKB). Hub and spoke tables were constructed
manually from inspection of the associated networks.
Upstream regulators were identified by the Causal Analysis
Algorithm, lodged within the parental IPA algorithm, using
“master” network information from the Ingenuity Knowledge
Base.
Statistics
The significance of differences in outcomes was computed
using Fishers exact test to calculate a two-tailed P-value, or
McNamar Test for the same purpose, using the STATA program.
Significance was taken to be represented by P < 0.05.
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